Takeda Raises Full-Year Outlook On Strong Mainstays
Exec Reshuffle, TAK-721 Dropped
Japan's largest pharma firm logs what was generally viewed by analysts as a solid fiscal third quarter, driven by growth for its portfolio of global products, leading to raised guidance for the full year despite one pipeline setback. There will also be multiple C-suite reshuffles come 1 April.
